Nippon Kayaku Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Nippon Kayaku Co. sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Nippon Kayaku Co.: 5 sponsored US clinical trials, none currently recruiting.
Nippon Kayaku Co. sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Triple-Negative Breast Cancer, with 1 trials.
Upper-quartile sponsor footprint
Nippon Kayaku Co. sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
NCT01238939
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
NCT01238952
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
NCT00951613
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
NCT00951054
Study of NK012 in Patients With Refractory Solid Tumors
NCT00542958
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Therapeutic Areas
How the Nippon Kayaku Co. early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Metastatic Triple-Negative Breast Cancer (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Nippon Kayaku Co.: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Nippon Kayaku Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Nippon Kayaku Co. page
5 registered trials is a research-attention snapshot, not an endorsement of Nippon Kayaku Co. or any single study.
- None of Nippon Kayaku Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Metastatic Triple-Negative Breast Cancer is the condition Nippon Kayaku Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Triple-Negative Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nippon Kayaku Co. pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.